Description: Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Home Page: www.alpineimmunesciences.com
188 East Blaine Street
Seattle,
WA
98102
United States
Phone:
206 788 4545
Officers
| Name | Title |
|---|---|
| Dr. Mitchell H. Gold M.D. | Exec. Chairman & CEO |
| Dr. Stanford Peng M.D., Ph.D. | Pres and Head of R&D |
| Mr. Paul Rickey | Sr. VP, CFO, Treasurer & Sec. |
| Dr. Wayne R. Gombotz | Chief Technology Officer |
| Temre Johnson | Head of IR & Corp. Communications |
| Dr. Remy Durand Ph.D. | Chief Bus. Officer |
| Dr. Pamela Holland Ph.D. | Sr. VP of Research |
| Dr. Andrew Seth Sandler M.D. | Chief Medical Officer |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5406 |
| Price-to-Sales TTM: | 9.1847 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 85 |